Research Progress on the Inhibitory Effect of Liver Active-Targeted Drug Delivery System on Liver Cancer
Objective To provide a reference for the research of novel liver active-targeted drug delivery system and related formulations.Methods Based on the literature related to the ligand-modified liver active-targeted drug delivery system in the CNKI,WanFang,VIP and PubMed from 2017 to 2023,the types of the system and its research status in the treatment of liver cancer(including the design of specific nanoparticles,the efficacy of targeted drug delivery system in vitro and in vivo,the existing challenges and the future development direction of this system)were summarized.Results and Conclusion The liver active-targeted drug delivery system is a novel drug delivery strategy emerging in recent years,which targets liver parenchymal cells,liver non-parenchymal cells and liver tumor cells.The specific markers on the surface of liver cancer cells were the main targets for targeted delivery of chemotherapy drugs,and nanoparticles are the most commonly used drug carriers in the liver active-targeted drug delivery system.Efficient,low-toxicity and specific delivery of drugs to liver cancer tissues can be realized by the material adjustment and surface modification of nanoparticles.There are still many key technologies that need to be improved for liver active-targeted drug delivery system,such as complex preparation processes,low drug loading,insufficient exploration and application of liver cell specific ligands,lack of transformation of a large number of carrier materials from experimental research to clinical application.However,the liver active-targeted drug delivery system has shown great superiority in targeted therapy for liver cancer,and its development trend and application prospect are worth paying attention to.
liver cancertargeted drug deliveryactive targetingacceptorligand
国家科技期刊平台
NSTL
万方数据
